| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 53.28 | 4267 |
| Intrinsic value (DCF) | 477691.18 | 39154915 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Sunshine Biopharma, Inc. (NASDAQ: SBFM) is a Canada-based pharmaceutical and nutritional supplement company specializing in the research and development of innovative anticancer drugs and antiviral treatments. The company's flagship drug candidate, Adva-27a, targets multidrug-resistant cancers, including pancreatic, breast, and lung cancers, while its SBFM-PL4 compound is being developed as an anti-coronavirus treatment under a license agreement with the University of Georgia. Additionally, Sunshine Biopharma markets science-based nutritional supplements, such as Essential 9 and Essential Calcium-Vitamin D. Operating in the competitive specialty and generic drug manufacturing sector, Sunshine Biopharma focuses on high-potential oncology and antiviral therapies, positioning itself as a niche player in the healthcare industry. With a market cap of approximately $6.56 million, the company remains in the clinical development stage, seeking to advance its pipeline toward commercialization.
Sunshine Biopharma presents a high-risk, high-reward investment opportunity due to its focus on early-stage oncology and antiviral drug development. The company's Adva-27a and SBFM-PL4 compounds target significant unmet medical needs, but clinical and regulatory hurdles remain. Financials reveal a net loss of $5.13 million in the latest period, with negative operating cash flow, indicating reliance on funding to sustain R&D. While the company holds $9.69 million in cash, its small market cap and beta of 1.235 suggest volatility. Investors should weigh the potential of its pipeline against the inherent risks of biotech investing, including lengthy development timelines and uncertain FDA approvals.
Sunshine Biopharma operates in the highly competitive oncology and antiviral drug development space, where it faces competition from well-funded biopharmaceutical giants and specialized biotech firms. The company's competitive advantage lies in its focus on multidrug-resistant cancers with Adva-27a, a differentiated podophyllotoxin derivative, and its antiviral SBFM-PL4 candidate. However, its small scale and limited resources compared to larger peers pose challenges in clinical trial execution and commercialization. Sunshine's nutritional supplement segment provides ancillary revenue but does not significantly differentiate it in the broader market. The company's partnership with the University of Georgia for SBFM-PL4 adds credibility, but its ability to secure additional collaborations or funding will be critical. Given its niche focus, Sunshine must demonstrate strong clinical data to attract potential partners or acquirers, as standalone commercialization may be difficult without substantial capital infusion.